Opticon Will Enhance Product Before Proceeding With Clinical Trial

Apr 18, 2001, 01:00 ET from Opticon Medical Inc.

    DUBLIN, Ohio, April 18 /PRNewswire/ -- Opticon Medical Inc.
 (OTC Bulletin Board:   OPMI) announced today that it will implement an
 engineering change to a feature of its OPTION-vf(TM) Urinary Catheter before
 proceeding with the clinical trial that it has organized.  "We have an
 opportunity to further affect both the value and the competitive strength of
 our product," said Opticon President, William Post.  "While incorporating this
 change translates to delaying our patient enrollment for a relatively brief
 period of time, we consider it essential to have our latest technology and the
 most recent embodiment of our development as the centerpiece of our clinical
 study.  All things considered, we think it's worth the trade off," Mr. Post
 said.
     With the filing of its Form 10-KSB last month, Opticon had previously
 announced its preparedness to begin the pivotal clinical trial which would
 support its efforts to gain regulatory clearance to market the first of the
 OPTION-v(TM) series of devices for use in short-term urinary management.  In
 its report, the Company stated that it had completed collaboration with
 representatives of the FDA in developing the study protocol, and had assembled
 its network of investigative sites.  In making today's announcement, the
 Company stated that it does not anticipate making any change to the study
 protocol when it returns to its investigators for beginning patient
 enrollment.
     Opticon Medical is a development stage medical device company engaged in
 the development and marketing of a series of innovative and cost-effective
 products for use in urology and in the management of urinary incontinence.
 
     Safe Harbor Statement Under the Private Securities Litigation Reform Act
 of 1995
     Statements in this news release that relate to other than strictly
 historical facts, such as statements about the Company's plans and strategies,
 expectations for future financial performance, new and existing products and
 technologies, and markets for the Company's products, are forward looking
 statements.  The words "believe," "expect," "anticipate," "estimate,"
 "project," and similar expressions identify forward-looking statements that
 speak only as of the date hereof.  Investors are cautioned that such
 statements involve risks and uncertainties that could cause actual results to
 differ materially from historical or anticipated results due to many factors
 including, but not limited to, the Company's lack of revenues or cash flow
 from operations, continuing losses and accumulated deficit, future capital
 needs, uncertainty of capital funding, product development risks, uncertainty
 of regulatory approval and market acceptance, dependence on a single product,
 dependence on others for manufacturing, lack of marketing and sales support,
 competition, and other risks detailed in the Company's most recent Annual
 Report on Form 10-KSB and other Securities and Exchange Commission filings.
 The Company undertakes no obligation to publicly update or revise any forward-
 looking statements.
 
 

SOURCE Opticon Medical Inc.
    DUBLIN, Ohio, April 18 /PRNewswire/ -- Opticon Medical Inc.
 (OTC Bulletin Board:   OPMI) announced today that it will implement an
 engineering change to a feature of its OPTION-vf(TM) Urinary Catheter before
 proceeding with the clinical trial that it has organized.  "We have an
 opportunity to further affect both the value and the competitive strength of
 our product," said Opticon President, William Post.  "While incorporating this
 change translates to delaying our patient enrollment for a relatively brief
 period of time, we consider it essential to have our latest technology and the
 most recent embodiment of our development as the centerpiece of our clinical
 study.  All things considered, we think it's worth the trade off," Mr. Post
 said.
     With the filing of its Form 10-KSB last month, Opticon had previously
 announced its preparedness to begin the pivotal clinical trial which would
 support its efforts to gain regulatory clearance to market the first of the
 OPTION-v(TM) series of devices for use in short-term urinary management.  In
 its report, the Company stated that it had completed collaboration with
 representatives of the FDA in developing the study protocol, and had assembled
 its network of investigative sites.  In making today's announcement, the
 Company stated that it does not anticipate making any change to the study
 protocol when it returns to its investigators for beginning patient
 enrollment.
     Opticon Medical is a development stage medical device company engaged in
 the development and marketing of a series of innovative and cost-effective
 products for use in urology and in the management of urinary incontinence.
 
     Safe Harbor Statement Under the Private Securities Litigation Reform Act
 of 1995
     Statements in this news release that relate to other than strictly
 historical facts, such as statements about the Company's plans and strategies,
 expectations for future financial performance, new and existing products and
 technologies, and markets for the Company's products, are forward looking
 statements.  The words "believe," "expect," "anticipate," "estimate,"
 "project," and similar expressions identify forward-looking statements that
 speak only as of the date hereof.  Investors are cautioned that such
 statements involve risks and uncertainties that could cause actual results to
 differ materially from historical or anticipated results due to many factors
 including, but not limited to, the Company's lack of revenues or cash flow
 from operations, continuing losses and accumulated deficit, future capital
 needs, uncertainty of capital funding, product development risks, uncertainty
 of regulatory approval and market acceptance, dependence on a single product,
 dependence on others for manufacturing, lack of marketing and sales support,
 competition, and other risks detailed in the Company's most recent Annual
 Report on Form 10-KSB and other Securities and Exchange Commission filings.
 The Company undertakes no obligation to publicly update or revise any forward-
 looking statements.
 
 SOURCE  Opticon Medical Inc.